How will UK’s fixed-fee scheme for antibiotics help tackle the growing health crisis?

  13 April 2022

Health campaigners hope that a move by the UK to introduce a fixed-fee model to finance the development of new antibiotics will boost worldwide efforts to combat the growing problem of resistance to existing drugs. The UK is to launch the world’s first “subscription” incentive scheme for antibiotics, which will pay manufacturers a flat rate for making new drugs available to the NHS, regardless of how much or how little they are used. The pilot scheme announced on Tuesday will initially offer Pfizer of the US and Shionogi of Japan contracts capped at £10mn a year each, to supply a new antibiotic for up to 10 years.

Further reading: Financial Times
Author(s): Clive Cookson
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!